A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.

ABSTRACT: Depression involves impairments in a range of cognitive and emotional capacities. It is unknown whether these functions can inform medication choice when considered as a composite predictive biomarker. We tested whether behavioral tests, grounded in the neurobiology of cognitive and emotional functions, predict outcome with common antidepressants. Medication-free outpatients with nonpsychotic major depressive disorder (N=1008; 665 completers) were assessed before treatment using 13 computerized tests of psychomotor, executive, memory-attention, processing speed, inhibitory, and emotional functions. Matched healthy controls (N=336) provided a normative reference sample for test performance. Depressed participants were then randomized to escitalopram, sertraline, or venlafaxine-extended rele

SUBMITTER: Etkin A 

PROVIDER: S-EPMC4397406 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature